Abstract
In recent years several mutations and sequence polymorphisms of the glucocorticoid receptor gene have been described. The majority of mutations have been found in patients with a rare endocrinological abnormality, the glucocorticoid resistance syndrome. In addition, some sequence polymorphisms have been considered to contribute to various diseases, but unambiguous correlations have not been established yet. Here we present the results of an in silico study, which revealed previously undescribed sequence variants of the glucocorticoid receptor gene. Although the three-dimensional structure of the DNA-binding domain of the glucocorticoid receptor has been known for several years, the crystal structure of the ligand-binding domain of the receptor has been published only recently. Using a comparative protein modelling, we analysed the structural relevance of known mutations as well as novel sequence variants discovered by our in silico approach in the ligand-binding domain of the glucocorticoid receptor. We conclude that comparative protein modelling of these mutant receptor variants offers a useful means to predict the functional consequences of amino acid replacements and to correlate structural abnormalities with clinical findings.
Keywords: glucocorticoid receptor, mutations, ligand-binding domain, in silico
Current Medicinal Chemistry
Title: Sequence Variants of the Ligand-Binding Domain of the Glucocorticoid Receptor Gene and their Functional Consequences on the Three- Dimensional Protein Structure
Volume: 11 Issue: 24
Author(s): Istvan Liko, Peter Igaz, Attila Patocs, Szilvia Toth, Tamas Pazmany, Miklos Toth and Karoly Racz
Affiliation:
Keywords: glucocorticoid receptor, mutations, ligand-binding domain, in silico
Abstract: In recent years several mutations and sequence polymorphisms of the glucocorticoid receptor gene have been described. The majority of mutations have been found in patients with a rare endocrinological abnormality, the glucocorticoid resistance syndrome. In addition, some sequence polymorphisms have been considered to contribute to various diseases, but unambiguous correlations have not been established yet. Here we present the results of an in silico study, which revealed previously undescribed sequence variants of the glucocorticoid receptor gene. Although the three-dimensional structure of the DNA-binding domain of the glucocorticoid receptor has been known for several years, the crystal structure of the ligand-binding domain of the receptor has been published only recently. Using a comparative protein modelling, we analysed the structural relevance of known mutations as well as novel sequence variants discovered by our in silico approach in the ligand-binding domain of the glucocorticoid receptor. We conclude that comparative protein modelling of these mutant receptor variants offers a useful means to predict the functional consequences of amino acid replacements and to correlate structural abnormalities with clinical findings.
Export Options
About this article
Cite this article as:
Liko Istvan, Igaz Peter, Patocs Attila, Toth Szilvia, Pazmany Tamas, Toth Miklos and Racz Karoly, Sequence Variants of the Ligand-Binding Domain of the Glucocorticoid Receptor Gene and their Functional Consequences on the Three- Dimensional Protein Structure, Current Medicinal Chemistry 2004; 11 (24) . https://dx.doi.org/10.2174/0929867043363749
DOI https://dx.doi.org/10.2174/0929867043363749 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endocannabinoid System: A Multi-Facet Therapeutic Target
Current Clinical Pharmacology Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Hypertension and Compliance to Treatment in the Primary Care Setting: Key Issues from the Literature Review
Current Hypertension Reviews Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Current Pharmaceutical Design Cardiac MRI in Autoimmune Diseases: Where Are We Now?
Current Cardiology Reviews Enhancement of Solubility and Permeability of Candesartan Cilexetil by Using Different Pharmaceutical Interventions
Current Drug Delivery Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Improving RBC K Transport and Hemoglobin-O2 Binding by Amiloride: A Novel Therapeutic Approach for Reversion of Angina and Myocardial Ischemia in Coronary Heart Diseases
Recent Patents on Cardiovascular Drug Discovery Excess Exposure to Insulin Is the Primary Cause of Insulin Resistance and its Associated Atherosclerosis
Current Molecular Pharmacology The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease
Current Vascular Pharmacology Pathophysiology of Hypertension During Preeclampsia: Role of Inflammatory Cytokines
Current Hypertension Reviews Antibody-Based Therapies in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry Oxidative Stress Drivers and Modulators in Obesity and Cardiovascular Disease: From Biomarkers to Therapeutic Approach
Current Medicinal Chemistry The Adrenergic System in Gastrointestinal Cancers
Current Cancer Therapy Reviews Glucocorticoid-Induced Hypertension and Tetrahydrobiopterin (BH4), a Common Cofactor for the Production of Vasoactive Molecules
Current Hypertension Reviews Left Ventricular Hypertrophy Beyond Hemodynamics: Genetic, Metabolic and Hormonal Factors
Current Hypertension Reviews The Heme Oxygenase System Selectively Modulates Proteins Implicated in Metabolism, Oxidative Stress and Inflammation in Spontaneously Hypertensive Rats
Current Pharmaceutical Design Lysophosphatidic Acid and Renal Fibrosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Clinical Evidence and Therapeutic Treatments at the Time of the Coronaviruses Responsible for SARS: A Perspective and Points of view with a Focus on Vascular Endothelium
Coronaviruses From Gene to Epigene-Based Therapies Targeting the Vascular Endothelium
Current Vascular Pharmacology